Prospective evaluation of neuromediators during treatment with docetaxel in castration resistant prostate cancer.

被引：0
|
作者：
von Hardenberg, Jost
Schwartz, Maike
Bolenz, Christian
Weiss, Christel
Werner, Thorsten
Fuxius, Stefan
Mueller, Markus
Frangenheim, Thomas
Heinrich, Elmar
机构：
[1] Univ Med Ctr Mannheim, Mannheim, Germany
[2] Heidelberg Univ, Mannheim Med Ctr, Dept Urol, Mannheim, Germany
[3] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Urol, Mannheim, Germany
[4] Outpatient Urol Practice Herzberg, Herzberg, Germany
[5] Tumor Ctr, Heidelberg, Germany
[6] Klinikum Ludwigshafen, Dept Urol, Ludwigshafen, Germany
[7] Outpatient Urol Practice, Bruchsal, Germany
[8] Klinikum Wels Grieskirchen, Wels, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e16609
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16609
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel
    Von Hardenberg, Jost
    Schwartz, Maike
    Werner, Thorsten
    Fuxius, Stefan
    Mueller, Markus
    Frangenheim, Thomas
    Bolenz, Christian
    Weiss, Christel
    Heinrich, Elmar
    ANTICANCER RESEARCH, 2017, 37 (09) : 5117 - 5124
  • [2] Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant
    Altavilla, Amelia
    Iacovelli, Roberto
    Procopio, Giuseppe
    Alesini, Daniele
    Risi, Emanuela
    Campenni, Giuseppe Maria
    Palazzo, Antonella
    Cortesi, Enrico
    CANCER BIOLOGY & THERAPY, 2012, 13 (11) : 1001 - 1008
  • [3] Antitumor activity of abiraterone, enzalutamide, and docetaxel following treatment with diethystilbestrol in castration-resistant prostate cancer.
    Assoun, Sandra
    Campedel, Luca
    Roupret, Morgan
    Vaessen, Christophe
    Parra, Jerome
    Boostandoost, Haide Angele
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [4] Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer
    Mangir, N.
    Turkeri, L.
    ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (08): : 515 - 522
  • [5] Is chemical/surgical castration necessary during docetaxel chemotherapy for castration-resistant prostate cancer?
    Watanabe, Masahito
    Kanao, Kent
    Muramatsu, Hiroyuki
    Morinaga, Shingo
    Kajikawa, Keishi
    Kobayashi, Ikuo
    Nishikawa, Genya
    Kato, Yoshiharu
    Nakamura, Kogenta
    Sumitomo, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] INTERMITTENT DOCETAXEL THERAPY FOR CASTRATION RESISTANT PROSTATE CANCER
    Kume, Haruki
    Nagata, Masayoshi
    Igawa, Yasuhiko
    Nishimatsu, Hiroaki
    Enomoto, Yutaka
    Nakagawa, Tohru
    Fujimura, Tetsuya
    Suzuki, Motofumi
    Homma, Yukio
    JOURNAL OF UROLOGY, 2013, 189 (04): : E320 - E321
  • [7] RE-TREATMENT WITH DOCETAXEL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (CRPC)
    Gernone, A. G.
    Troccoli, G. T.
    Pagliarulo, V. P.
    Pagliarulo, A. P.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 283 - 283
  • [8] RE-TREATMENT WITH DOCETAXEL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (CRPC)
    Gernone, Angela
    Troccoli, Giuseppe
    Pagliarulo, Vincenzo
    Pagliarulo, Arcangelo
    JOURNAL OF UROLOGY, 2010, 183 (04): : E228 - E228
  • [9] Treatment patterns in men with castration-resistant prostate cancer receiving docetaxel
    Davis, Keith L.
    Gutierrez, Benjamin
    Zyczynski, Teresa Maria
    Kaye, James A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer.
    Sella, Avishay
    Sella, Tal
    Peer, Avivit
    Berger, Raanan
    Frank, Stephen Jay
    Gez, Eliahu
    Sharid, David
    Hayat, Henry
    Rosenbaum, Eli
    Neiman, Victoria
    Keizman, Daniel
    Kovel, Svetlana
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345